Skip to main content

NIH botched biolab safety study: NRC

The NIH's safety assessment of a linkurl:controversial Boston University laboratory;https://www.the-scientist.com/news/display/24679/ did not thoroughly develop worst case scenarios or adequately compare safety risks at other proposed sites, finds a linkurl:National Research Council report.;https://www.nap.edu/catalog.php?record_id=12073 The council released its 28-page report yesterday (November 29th) after the Massachusetts government commissioned it to review the NIH appraisal, which had linku

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
The NIH's safety assessment of a linkurl:controversial Boston University laboratory;https://www.the-scientist.com/news/display/24679/ did not thoroughly develop worst case scenarios or adequately compare safety risks at other proposed sites, finds a linkurl:National Research Council report.;https://www.nap.edu/catalog.php?record_id=12073 The council released its 28-page report yesterday (November 29th) after the Massachusetts government commissioned it to review the NIH appraisal, which had linkurl:concluded;https://www.nems.nih.gov/aspects/nat_resources/programs/nepa2.cfm in July 2007 that the site chosen to build the laboratory was the safest among three possible sites. But according to the council's report, "The conclusions reached in the [NIH] report are not adequately supported by the analyses." The linkurl:biodefense laboratory,;https://www.the-scientist.com/news/display/23076/ which will include a linkurl:Biosafety Level 4 facility,;https://www.the-scientist.com/news/display/53626 has faced linkurl:opposition;https://www.the-scientist.com/news/display/23468 from residents in the South End area of Boston where the lab is being built. Yesterday's report concluded that the NIH assessment did not use appropriate pathogens in its models of worst case scenarios. "A more suitable analysis would have included the selection of agents that are more transmissible and thus might have created a greater risk of urban outbreaks," the council's report states. The NIH's report also did not specify the assumptions made in determining worst case scenario models, John Ahearne, emeritus director of the ethics program at Sigma Xi, said in a press release. According to the __Boston Globe's__ linkurl:report;https://tinyurl.com/yt6zvx today, opponents hope the council's report will help sway judges who are considering whether or not the lab should open.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo